Verlen Labs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.70 M
- Revenue Growth 131.83%
- Profit Growth 143.74%
- Ebitda 54.68%
- Net Worth 205.56%
- Total Assets 73.47%
About Verlen Labs
Verlen Labs Private Limited (VLPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 August 2016 (Eight years and five months 15 days old ). Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹9.70 M.
Tripura Borra and Borra Udayabaskar serve as directors at the Company.
Company Details
-
Location
Rangareddy, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100TG2016PTC111560
-
Company No.
111560
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Aug 2016
-
Date of AGM
27 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Verlen Labs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tripura Borra
|
Managing Director | 10-Jul-2017 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Borra Udayabaskar
|
Director | 22-Aug-2016 | Current |
Financial Performance of Verlen Labs.
Verlen Labs Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 131.83% increase. The company also saw a substantial improvement in profitability, with a 143.74% increase in profit. The company's net worth Soared by an impressive increase of 205.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Verlen Labs?
Unlock access to Verlen Labs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Ekard Life Sciences Private LimitedBorra Udayabaskar is a mutual person
Charges (Loans)
₹9.70 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.97 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 May 2022 | Axis Bank Limited | ₹9.70 M | Open |
How Many Employees Work at Verlen Labs?
Unlock and access historical data on people associated with Verlen Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Verlen Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Verlen Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
